Berger R, Trannoy E, Holländer G, Bailleux F, Rudin C, Creusvaux H
University Children's Hospital, Basel, Switzerland.
J Infect Dis. 1998 Nov;178 Suppl 1:S99-103. doi: 10.1086/514265.
Decreased cell-mediated immune (CMI) response to varicella-zoster virus (VZV) is correlated with an increased risk of reactivation of latent virus from dorsal root sites, leading to herpes zoster. The cell-mediated and humoral immunogenicity of three concentrations (3200, 8500, and 41,650 pfu/dose) of a live attenuated VZV vaccine (Oka strain; VZV/Oka) was compared with a control pneumococcal polysaccharide vaccine in 200 healthy adults who were > or = 55 years old. Six weeks after vaccination, the VZV-specific CMI response (as measured by stimulation index values and precursor cell frequencies) was enhanced in all VZV/Oka vaccine groups compared with the control group (for all VZV/Oka groups combined vs. controls, tested with VZV crude antigen: stimulation index, P < .001; precursor cell frequency, P < .001). Geometric mean titers of anti-VZV antibodies increased in all VZV/Oka vaccine groups but remained unchanged in the control vaccine group. No dose effect of VZV/Oka vaccine was observed for CMI or humoral responses.
对水痘-带状疱疹病毒（VZV）的细胞介导免疫（CMI）反应降低与潜伏病毒从背根部位重新激活导致带状疱疹的风险增加相关。在200名年龄≥55岁的健康成年人中，将三种浓度（3200、8500和41,650 pfu/剂量）的减毒活VZV疫苗（Oka株；VZV/Oka）的细胞介导免疫原性和体液免疫原性与对照肺炎球菌多糖疫苗进行了比较。接种疫苗六周后，与对照组相比，所有VZV/Oka疫苗组的VZV特异性CMI反应（通过刺激指数值和前体细胞频率测量）均增强（所有VZV/Oka组合并与对照组相比，用VZV粗抗原检测：刺激指数，P <.001；前体细胞频率，P <.001）。所有VZV/Oka疫苗组中抗VZV抗体的几何平均滴度均升高，但对照疫苗组中保持不变。未观察到VZV/Oka疫苗对CMI或体液反应的剂量效应。
